AbbVie Inc. $ABBV Stock Position Lifted by WASHINGTON TRUST Co

WASHINGTON TRUST Co lifted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 9.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 31,308 shares of the company’s stock after purchasing an additional 2,647 shares during the quarter. WASHINGTON TRUST Co’s holdings in AbbVie were worth $7,249,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Smart Money Group LLC raised its position in shares of AbbVie by 1.1% during the 3rd quarter. Smart Money Group LLC now owns 4,822 shares of the company’s stock worth $1,116,000 after buying an additional 54 shares in the last quarter. Bright Futures Wealth Management LLC. bought a new stake in AbbVie during the third quarter worth approximately $220,000. Journey Strategic Wealth LLC lifted its position in AbbVie by 1.1% in the third quarter. Journey Strategic Wealth LLC now owns 23,317 shares of the company’s stock worth $5,399,000 after purchasing an additional 265 shares during the period. Arete Wealth Advisors LLC increased its position in shares of AbbVie by 0.4% during the 3rd quarter. Arete Wealth Advisors LLC now owns 30,689 shares of the company’s stock valued at $7,100,000 after purchasing an additional 133 shares during the period. Finally, Creekmur Asset Management LLC raised its stake in shares of AbbVie by 17.9% in the 3rd quarter. Creekmur Asset Management LLC now owns 18,963 shares of the company’s stock worth $4,391,000 after buying an additional 2,884 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Citigroup reduced their price objective on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research report on Tuesday, January 27th. HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and lifted their price target for the company from $225.00 to $265.00 in a research report on Wednesday, December 10th. Evercore cut their target price on AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research note on Wednesday, February 4th. Wall Street Zen upgraded AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a research note on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and an average price target of $253.15.

Insider Transactions at AbbVie

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.25% of the company’s stock.

AbbVie Stock Up 3.1%

NYSE ABBV opened at $231.69 on Monday. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The company has a market cap of $409.66 billion, a price-to-earnings ratio of 98.17, a price-to-earnings-growth ratio of 0.81 and a beta of 0.35. The business’s fifty day moving average is $224.34 and its 200 day moving average is $223.26.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.06. The business had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. AbbVie’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio is currently 293.22%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.